Kawada Hiroshi, Nagata Shoma, Noda Yoshifumi, Kawai Nobuyuki, Ando Tomohiro, Kaga Tetsuro, Suto Taketo, Kondo Hiroshi, Matsuo Masayuki
Department of Radiology, Gifu University, Japan.
Department of Radiology, Teikyo University, Japan.
Interv Radiol (Higashimatsuyama). 2024 Mar 27;10:e20230026. doi: 10.22575/interventionalradiology.2023-0026. eCollection 2025 Mar 28.
Nonocclusive mesenteric ischemia (NOMI) is a condition characterized by segmental or discontinuous mesenteric ischemia and intestinal necrosis without an organic obstruction in the mesenteric vessels. Diagnosis is challenging, and early intervention is crucial for improving patient outcomes. Various factors such as background factors, symptoms, biomarkers, and imaging techniques contribute to the diagnosis. Ensuring an early diagnosis and prompt treatment is of paramount importance. Although studies reported on the effectiveness of intra-arterial vasodilator infusion therapy as an endovascular treatment, its future role remains uncertain. Therefore, this review primarily aimed to provide a comprehensive summary of the advancements in the current state of NOMI management, with a specific emphasis on the implementation of endovascular therapy.
非闭塞性肠系膜缺血(NOMI)是一种以节段性或连续性肠系膜缺血及肠坏死为特征的疾病,而肠系膜血管无器质性梗阻。诊断具有挑战性,早期干预对于改善患者预后至关重要。多种因素如背景因素、症状、生物标志物及影像学技术都有助于诊断。确保早期诊断和及时治疗至关重要。尽管有研究报道了动脉内血管扩张剂输注疗法作为一种血管内治疗的有效性,但其未来作用仍不确定。因此,本综述主要旨在全面总结NOMI管理现状的进展,特别强调血管内治疗的实施。